eritoran

Small moleculeexperimental

Eritoran is a synthetic lipid that inhibits the receptor TLR4. It was developed as a potential treatment for severe sepsis, an excessive inflammatory response to an infection. It failed a five year Phase III clinical trial, the results of which were published in 2013, and as of 2014 was no longer being developed. — Wikipedia

Clinical trial activity

5 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2001 (NCT00046072)

Timeline

2000s

Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
Jan 1, 2008
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Toll-like receptor 4/MD-2ANTAGONIST
Toll-like receptor 4/MD-2 antagonist
Competes with LPS for binding to the TLR4 receptor complex blocking the activation of NF-kB and production of inflammatory mediators, such as TNF-a and IL6, in response to LPS
Binds to the hydrophobic pocket of the MD2 portion of the TLR4 receptor complex
- Toll-like receptor 4 (TLR4) ↗
- Lymphocyte antigen 96 (LY96) ↗
- Toll-like receptor 4
- Lymphocyte antigen 96

Chemistry & pharmacology

Loading structure…

SMILES

CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)(O)O)[C@@H]1OCC[C@@H](CCCCCCC)OC

Mol. weight: 1313.68 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

3-o-decyl-2-deoxy-6-o-(2-deoxy-3-o-(3-methoxydecyl)-6-o-methyl-2-((1-oxo-11-octadecenyl)amino)-4-o-phosphonoglucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-1-(dihydroxy phosphate)glucopyranose
b1287
b1287
b1287
b 1287
b1287 saccharide
e5564
e5564
e5564
eritoran
eritoran
eritoran
eritoran
eritoran
eritoran
eritoran
eritoran sodium
eritoran tetrasodium
eritoran tetrasodium
eritoran tetrasodium
eritoran tetrasodium
eritoran tetrasodium
eritoran tetrasodium

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02267317	Phase 2	Jan 1, 2015	Department of Veteran Affairs, University of Texas, San Antonio
NCT02321111	Phase 2	Jan 1, 2015	University of Texas, San Antonio
NCT00756912	Phase 1	Sep 1, 2008	Case Western Reserve University, Eisai
NCT00334828	Phase 3	Jun 1, 2006	Eisai
NCT00046072	Phase 2	Oct 1, 2001	Eisai

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Eisai	For profit	3	3	3	2001
University of Texas, San Antonio	Academic/Hospital	2	2	1	2015
Case Western Reserve University	Academic/Hospital	1	0	1	2008
Department of Veteran Affairs	Government	1	0	1	2015

4 organizations

Page 1 / 1